KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATLeasesLong-Term Debt IssuancesOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)R&D In ProcessReceivables - NetShort-Term Debt repayments
Ratios

Pfizer (PFE) Leases (2019 - 2025)

Pfizer (PFE) has disclosed Leases for 7 consecutive years, with $2.2 billion as the latest value for Q4 2025.

  • Quarterly Leases fell 3.32% to $2.2 billion in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $2.2 billion through Dec 2025, down 3.32% year-over-year, with the annual reading at $2.2 billion for FY2025, 3.32% down from the prior year.
  • Leases for Q4 2025 was $2.2 billion at Pfizer, down from $2.3 billion in the prior quarter.
  • The five-year high for Leases was $3.0 billion in Q4 2022, with the low at $2.2 billion in Q4 2025.
  • Average Leases over 5 years is $2.7 billion, with a median of $2.8 billion recorded in 2021.
  • The sharpest move saw Leases soared 104.83% in 2021, then fell 21.72% in 2024.
  • Over 5 years, Leases stood at $2.8 billion in 2021, then increased by 5.74% to $3.0 billion in 2022, then decreased by 2.6% to $2.9 billion in 2023, then dropped by 21.72% to $2.3 billion in 2024, then dropped by 3.32% to $2.2 billion in 2025.
  • According to Business Quant data, Leases over the past three periods came in at $2.2 billion, $2.3 billion, and $2.9 billion for Q4 2025, Q4 2024, and Q4 2023 respectively.